Conventional versus drug-eluting beads chemoembolization for infiltrative hepatocellular carcinoma: a comparison of efficacy and safety
Open Access
- 29 November 2019
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Cancer
- Vol. 19 (1), 1-10
- https://doi.org/10.1186/s12885-019-6386-6
Abstract
To compare the efficacy and safety between conventional transarterial chemoembolization (cTACE) and drug-eluting beads TACE (DEB-TACE) in patients with infiltrative hepatocellular carcinoma (iHCC). A total of 89 iHCC patients who were treated with either cTACE (n = 33) or DEB-TACE (n = 56) between April 2013 and September 2017 were included in this retrospective study. Patients with the situations that might have a poor outcome were defined as advanced disease including Child-Pugh class B, bilobar lesions, tumor size greater than 10 cm, ECOG 1–2, tumor burden of 50–70%, and the presence of ascites, arterioportal shunt (APS), and portal venous tumor thrombus (PVTT). The tumor response was measured 1-month and 3-month after the procedure. Progression-free survival (PFS) was calculated. Toxicity was graded by Common Terminology Criteria for Adverse Events v5.0 (CTCAE v5.0). The differences in tumor response, PFS, and toxicity were compared between the DEB-TACE group and cTACE group. At 1-month and 3-month after the procedure, the objective response rate (ORR) in the overall study population was similar in DEB-TACE group and cTACE group. The disease control rate (DCR), at 1-month after the procedure, was significantly higher in the patients treated with DEB-TACE relative to those treated with cTACE (P = 0.034), while after 3 months, the difference did not differ between two groups. DEB-TACE showed a higher DCR than cTACE in patients with tumor size greater than 10 cm (P = 0.036) or associated with APS (P = 0.030) at 1-month after the procedure, while after 3 months, the difference was only noted in patients with APS (P = 0.036). The median PFS in DEB-TACE group was 96 days, while in cTACE group was 94 days, and there was no difference in PFS between two groups (P = 0.831). In the side effect analysis, abdominal pain (P = 0.034) and fever (P = 0.009) were more frequently present in the cTACE group than DEB-TACE group, but there was no difference in high grade liver toxicity between the two groups. Compared to cTACE, DEB-TACE offers slightly better DCR and tolerability for iHCC patients, particularly in patients associated with APS and large tumor size. However, DEB-TACE does not provide higher PFS than cTACE.Keywords
Funding Information
- National Natural Science Foundation of China (81801813)
This publication has 32 references indexed in Scilit:
- Radiologic response to transcatheter hepatic arterial chemoembolization and clinical outcomes in patients with hepatocellular carcinomaLiver International, 2013
- Factors Associated With Outcomes and Response to Therapy in Patients With Infiltrative Hepatocellular CarcinomaClinical Gastroenterology and Hepatology, 2013
- Survival of infiltrative hepatocellular carcinoma patients with preserved hepatic function after treatment with transarterial chemoembolizationZeitschrift für Krebsforschung und Klinische Onkologie, 2013
- Is transarterial chemoembolization beneficial for patients with diffuse infiltrative hepatocellular carcinoma?Hepatology International, 2012
- Diffuse Infiltrative Hepatocellular Carcinoma: Assessment of Presentation, Treatment, and OutcomesAnnals of Surgical Oncology, 2012
- Infiltrating Hepatocellular Carcinoma: Seeing the Tree through the ForestJournal of Gastrointestinal Surgery, 2011
- Modified RECIST (mRECIST) Assessment for Hepatocellular CarcinomaSeminars in Liver Disease, 2010
- Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V StudyCardioVascular and Interventional Radiology, 2009
- Hepatocellular carcinoma of diffuse type: MR imaging findings and clinical manifestationsJournal of Magnetic Resonance Imaging, 2003
- Evidence for an association between the aetiology of cirrhosis and pattern of hepatocellular carcinoma developmentGut, 2001